The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Neoleukin Therapeutics, Inc(NASDAQ:NLTX) 
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines inte...
Website: http://www.neoleukin.com
Full Time Employees: 65
CEO: Jonathan G. Drachman
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Share this website to your friends
Neoleukin Therapeutics Op Cashflow Per Share ttm
Neoleukin Therapeutics Free Cashflow Per Share ttm
Neoleukin Therapeutics Cash Per Share ttm
Neoleukin Therapeutics (GAAP) P/E ratio ttm
Neoleukin Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.